Indication
Hodgkin lymphoma refractory
2 clinical trials
5 products
Product
NivolumabClinical trial
Phase 1b Study Evaluating the Safety and Efficacy of Autologous CD30.CAR-T in Combination With PD-1 Checkpoint Inhibitor (Nivolumab) in Relapsed or Refractory Classical Hodgkin Lymphoma Patients After Failure of Frontline Therapy (ACTION)Status: Active (not recruiting), Estimated PCD: 2025-12-15
Product
CD30.CAR-TProduct
FludarabineProduct
BendamustineClinical trial
A Phase 2 Multi-Center Study Evaluating the Safety and Efficacy of CD30-Directed Genetically Modified Autologous T Cells (CD30.CAR-T) in Adult and Pediatric Patients With Relapsed or Refractory Classical Hodgkin LymphomaStatus: Active (not recruiting), Estimated PCD: 2025-05-01
Product
Autologous CD30.CAR-T